H. Ito

发表

Safety and efficacy of intensive instillation of low-dose pirarubicin vs. bacillus Calmette-Guérin in patients with high-risk non-muscle-invasive bladder cancer.

C. Ohyama, K. Yoshikawa, S. Hatakeyama, 2020, Urologic oncology.

Risk-stratified surveillance and cost effectiveness of follow-up after radical cystectomy in patients with muscle-invasive bladder cancer.

C. Ohyama, T. Koie, K. Yoshikawa, 2017, Oncotarget.

Risk score-based substratification improves surveillance costs after transurethral resection of bladder tumor in patients with primary high-risk non-muscle-invasive bladder cancer

C. Ohyama, K. Yoshikawa, S. Hatakeyama, 2022, Scientific Reports.

Single immediate instillation of chemotherapy is associated with decreased recurrence and progression in patients with high‐risk non‐muscle‐invasive bladder cancer who receive adjuvant induction bacillus Calmette‐Guérin therapy

C. Ohyama, K. Yoshikawa, S. Hatakeyama, 2022, International journal of urology : official journal of the Japanese Urological Association.

Oncological outcomes of neoadjuvant chemotherapy in patients with locally advanced upper tract urothelial carcinoma: a multicenter study

C. Ohyama, Toshikazu Tanaka, T. Koie, 2017, Oncotarget.

Impact of neoadjuvant chemotherapy–induced acute kidney injury on oncological outcomes in patients who underwent radical cystectomy: A multicenter retrospective study.

C. Ohyama, K. Yoshikawa, S. Hatakeyama, 2023, Journal of Clinical Oncology.

Serum N-glycan profiling is a potential biomarker for castration-resistant prostate cancer

C. Ohyama, S. Nishimura, T. Matsumoto, 2019, Scientific Reports.

Preoperative chronic kidney disease predicts poor oncological outcomes after radical nephroureterectomy in patients with upper urinary tract urothelial carcinoma

C. Ohyama, T. Matsumoto, Toshikazu Tanaka, 2017, Oncotarget.

Combination of Muscle Quantity and Quality Is Useful to Assess the Necessity of Surveillance after a 5-Year Cancer-Free Period in Patients Who Undergo Radical Cystectomy: A Multi-Institutional Retrospective Study

C. Ohyama, K. Yoshikawa, S. Hatakeyama, 2023, Cancers.

Impact of an optimized surveillance protocol based on the European Association of Urology substratification on surveillance costs in patients with primary high-risk non-muscle-invasive bladder cancer

C. Ohyama, K. Yoshikawa, S. Hatakeyama, 2023, PloS one.

Characteristics of α2,3‐sialyl N‐glycosylated PSA as a biomarker for clinically significant prostate cancer in men with elevated PSA level

T. Habuchi, N. Tsuchiya, C. Ohyama, 2021, The Prostate.

Prognostic impact of eligibility for adjuvant immunotherapy in locally advanced urothelial cancer

C. Ohyama, Toshikazu Tanaka, S. Hatakeyama, 2021, BJUI compass.

Risk-stratified surveillance and cost effectiveness of follow-up after radical cystectomy in patients with muscle-invasive bladder cancer

C. Ohyama, T. Koie, K. Yoshikawa, 2017, Oncotarget.

Impact of severe acute kidney injury on short-term mortality in urosepsis

C. Ohyama, K. Yoshikawa, S. Hatakeyama, 2024, World journal of urology.